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Background: Metabolic acidosis is more common with advancing chronic kidney disease, and has been associated
with impaired physical function, impaired bone health, accelerated decline in kidney function and increased
vascular risk. Although oral sodium bicarbonate is widely used to correct metabolic acidosis, there exist potential
risks of therapy including worsening hypertension and fluid overload. Little trial evidence exists to decide whether
oral bicarbonate therapy is of net benefit in advanced chronic kidney disease, particularly in older people who are
most commonly affected, and in whom physical function, quality of life and vascular health are at least as
important outcomes as decline in renal function.
Methods/Design: BiCARB is a multi-centre, double-blind, placebo controlled, randomised trial evaluating the
clinical and cost-effectiveness of oral sodium bicarbonate in the management of older people with chronic kidney
disease and severely reduced glomerular filtration rate (GFR) who have a mild degree of metabolic acidosis. The
trial will recruit 380 patients from renal, Medicine for the Elderly, and primary care services across centres in the
United Kingdom. Male and female patients aged 60 years and older with an estimated glomerular filtration rate
of <30 mL/min/1.73 m2, not on dialysis, and with serum bicarbonate concentrations <22 mmol/L will be eligible for
participation. The primary clinical outcome for the trial is the between-group difference in the Short Physical
Performance Battery score at 12 months. Secondary outcomes include muscle strength, quality of life measured
using the EQ-5D score and KDQoL tools, cost effectiveness, renal function, presence of albuminuria and blood
pressure. Markers of bone turnover (25-hydroxyvitamin D, 1,25-hydroxyvitamin D, tartrate-resistant acid
phosphatase-5b and bone-specific alkaline phosphatase) and vascular health (B-type natriuretic peptide) will be
measured. Participants will receive a total of 24 months of either bicarbonate or placebo. The results will provide
the first robust test of the overall clinical and cost-effectiveness of this commonly used therapy in older patients
with severely reduced kidney function.
Trial registration: www.isrctn.com; ISRCTN09486651, registered 17 February 2012
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Chronic Kidney Disease (CKD) is common: 5 % of the
population of the United Kingdom has an estimated glom-
erular filtration rate (eGFR) of <60 mL/min/1.73 m2 (that
is, GFR stages 3 to 5), and rates in people over 70 are five
times higher than this [1]. Population-based estimates sug-
gest a prevalence of advanced CKD (GFR 15 to 29 mL/
min/1.73 m2) of approximately 2 % in those aged 70 and
over [2], and approximately 20 % of such patients will have
a degree of metabolic acidosis, with rates increasing as renal
function declines [3]. The introduction of routine eGFR
reporting by laboratories has increased the number of older
patients diagnosed with CKD, and bicarbonate is often used
to treat older people with low serum bicarbonate concen-
trations. Trial evidence to underpin the effectiveness and
safety of this intervention is, however, lacking [4], and this
lack of evidence is reflected in current guidelines, including
the Kidney Disease Improving Global Outcomes (KDIGO),
Scottish Intercollegiate Guidelines Network (SIGN) and
UK National Institute for Health and Care Excellence
(NICE) guidelines, which either give guidance based on ex-
pert consensus without underpinning evidence or note that
it is not currently possible to make an evidence-based rec-
ommendation regarding correction of mild to moderate
metabolic acidosis in CKD. There is variability in clinical
practice with regard to the use of bicarbonate therapy in
patients with CKD and mild acidosis. Measurement and
correction of acidosis is often part of standard care for pa-
tients managed under renal services but is less common for
patients managed by primary care or Medicine for the Eld-
erly services.
Older people are the group most likely to have CKD,
but despite this, few trials have included many older
people with CKD. Older patients with CKD invariably
have a wide range of comorbid diseases. A narrow focus
on kidney disease indices alone is therefore unlikely to
reflect what is important to the patient, and the narrow
focus on single diseases is a justifiable criticism of many
guidelines, which when applied to older people with
multi-morbidity may not provide a net gain in health or
wellbeing [5, 6]. It is thus important to measure a range
of outcomes of relevance to older people, seeking evi-
dence of both benefit and harm.
Potential benefits of bicarbonate therapy
Chronic acidosis has been associated with the following
biological effects [7]: muscle weakness [8], leading to fatigue
and falls; weight loss and increased protein breakdown [9];
increased bone resorption leading to osteoporosis [10];
worsening of hyperkalemia leading to arrhythmias; im-
paired glucose homeostasis [11]; and deranged thyroid
function [12], with some evidence that bicarbonate therapy
can reverse these physiological derangements. Acidosis may
also cause the following, although the existing evidence isless clear: acceleration of decline in renal function [13, 14];
worsening cardiac function, leading to decompensated
heart failure; and worsening of cardiovascular disease [7].
Potential adverse effects of bicarbonate therapy
Bicarbonate is awkward to take, as tablets are large, and
multiple tablets usually need to be taken. Sodium bicarbon-
ate contains 6 mmol of sodium per 500 mg, which could
lead to increased blood pressure (50 mmol of sodium per
day has been projected to increase systolic blood pressure
by 3.6 to 5.6 mmHg) [15] and fluid overload. Observational
studies suggest that higher serum bicarbonate is associated
with an increased risk of heart failure in patients with CKD
[16]. There is also a possible effect on vascular calcification
[7]; raising the blood pH may make calcium and phosphate
less soluble, thus promoting precipitation of calcium phos-
phate within vessel walls. Abdominal discomfort and bloat-
ing are recognized side effects listed in the British National
Formulary (BNF), perhaps via generation of carbon dioxide
in the gut.
The need for patient-centred outcomes in older people
with chronic kidney disease
An approach examining function and quality of life is
therefore essential to test whether bicarbonate interven-
tion in older people has overall worthwhile benefit.
Physical function and quality of life are the outcomes
that older people themselves consider to be the most
important [17] as evidenced by a Delphi consensus ex-
ercise involving both older patients and clinicians caring
for older people, with postponement of death being a
less important goal of therapy.
Our approach in designing this study was therefore to
focus first and foremost on indices of physical and psy-
chosocial function and quality of life, underpinned by
measures of muscle function that correlate with daily ac-
tivities and which predict future dependence. Added to
these are a series of outcomes examining the effect of
the intervention on the major associated disease states -
renal function, bone health and cardiovascular health, as
well as outcomes designed to quantify the side effects
and risks including hypertension and heart failure. A
comprehensive health economic analysis is integrated
into the trial to provide evidence of cost-effectiveness to
underpin policy and guideline production.
Existing trial evidence
In the preparation of this trial, literature searches of
MEDLINE, EMBASE and the Cochrane Library were per-
formed, using the search terms: older, elderly, acidosis,
kidney disease, CKD, NaHCO3, and bicarbonate. Searches
were augmented by checking the reference lists of articles
known to be highly relevant and relevant review articles.
No systematic reviews were found addressing this topic at
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a systematic review [18] has been published which sug-
gests that bicarbonate therapy may improve eGFR (by 3.2
mL/min/1.73 m2), reduce progression to end-stage renal
failure, but increase diastolic blood pressure (by 2.8
mmHg). However, only three trials of long-term (>2
months) therapy were included, with only 250 patients en-
rolled, and one trial [19] enrolled patients with a mean
eGFR of 75 mL/min/1.73 m2 and mean baseline serum bi-
carbonate of 26 mmol/L.
A preliminary, single-centre randomized controlled trial
comparing bicarbonate supplementation with placebo
showed a promising reduction in the rate of deterioration
of renal function with bicarbonate supplementation [13],
as well as improvements in muscle mass measured by
mid-arm muscle circumference. However, participants in
this trial were younger (mean age 55 years), and the trial
did not attempt to measure patient-centred outcomes
such as physical function and quality of life, and did not
evaluate the impact of bicarbonate therapy on markers of
bone and vascular health.
The imperative for the BiCARB trial
Chronic kidney disease is common and affects many older
people. The accompanying acidosis may worsen the muscle
weakness that affects many older people, which is a key risk
factor for death and institutionalization [20, 21]. Both falls
and osteoporosis lead to 60,000 hip fractures per year in
the UK, with 30 % mortality at 1 year [22] and frequent
institutionalization. The cost of falls alone has been esti-
mated to exceed £1 billion per year in the UK [23].
Although not all older people with CKD progress to end-
stage renal failure requiring dialysis, the effect on quality of
life and cost burden from dialysis is considerable: between
£15000 and £35000 per patient per year, depending on mo-
dality and setting of dialysis [24]. Finally, cardiovascular dis-
ease is the leading cause of hospitalization and death in
older people and is responsible itself for one-half to one-
third of the decline in physical function seen with age [25].
Thus, an intervention that successfully reverses acidosis in
this older population may be able to simultaneously im-
prove multiple important, associated comorbidities in
older people, with consequent improvements in function
and quality of life, as well as potential reductions in
hospitalization and later institutionalization. It is against
this background that the UK National Institute for Health
Research (NIHR) Health Technology Assessment
programme commissioned this trial to examine the effect-
iveness of oral bicarbonate therapy in older CKD patients
with acidosis.
Trial objectives
The primary objective of the BiCARB trial is to determine
whether oral bicarbonate therapy improves physicalfunction compared to placebo in older people with CKD
and mild acidosis. The secondary objectives are a) to deter-
mine whether oral bicarbonate therapy improves health-
related quality of life compared to placebo; to compare the
impact of oral bicarbonate therapy against placebo on bio-
chemical markers of chronic kidney disease, c) to assess
whether use of oral bicarbonate therapy is associated with
an excess of adverse events compared with placebo; d) to
estimate the cost-effectiveness of using oral bicarbonate
therapy compared with placebo, and e) to assess the effect
of oral bicarbonate therapy compared with placebo on bone
turnover and vascular health as assessed by biochemical
markers.
Methods/Design
Study design
The trial design is a randomised, double-blind, parallel
group, placebo controlled trial, analysed by intention to
treat. The treatment and follow-up will last 2 years for
each participant. Key outcomes will include measures of
physical function, quality of life, progression of renal dis-
ease, bone turnover, vascular health and adverse events.
A comprehensive health economic analysis is embedded
in the trial.
Study population
The study will recruit 380 community-dwelling partici-
pants aged 60 and older with GFR <30 mL/min/1.73 m2,
not on renal replacement therapy, with a serum bicarbon-
ate concentration of <22 mmol/L (the lower limit of the
reference range in most UK centres). Potential partici-
pants will be recruited from both primary care and
through secondary care sites, for example, renal clinics,
Medicine for the Elderly clinics, general Medicine clinics,
diabetes clinics, hypertension clinics and cardiovascular
clinics at each site. At each centre, the local investigator
and renal physicians, renal specialist nurses, geriatricians,
cardiologists and diabetologists will be assisted by the
study research nurses to identify potential participants.
Where local patient registries are kept, these will be
exploited to search for potentially suitable participants.
Primary care recruitment will be carried out with the
assistance of the primary care research networks in
Scotland (SPCRN) and England (CRN). Network in-
volvement via the Ageing and Renal UKCRN specialty
groups will assist with recruitment, access to patients
and access to network research nurse time. Table 1 gives
the inclusion and exclusion criteria for the trial. Poten-
tial participants already taking oral bicarbonate therapy
will have the option to enter the trial after a 3-month
washout period. Written informed consent will be ob-
tained from all participants prior to enrolment. Research
ethics committee approval has been given by the East of
Scotland Research Ethics Committee (ref 12/ES/0023),
Table 1 Inclusion and exclusion criteria for the BiCARB trial
Inclusion criteria:
Participant is willing and able to give informed consent for participation
in the study
Male or female aged 60 years or above
Last known estimated glomerular filtration rate (eGFR) <30 ml/min/1.73 m2
by MDRD4 equation
Serum bicarbonate <22 mmol/L
Able (in the investigator’s opinion) and willing to comply with all study
requirements.
Exclusion criteria:
Severe cognitive impairment precluding written informed consent
Already taking bicarbonate therapy unless a 3-month washout period
is planned
Documented renal tubular acidosis (likely to require bicarbonate, often
in very large doses)
On renal replacement therapy (haemodialysis or peritoneal dialysis)
Anticipated to start renal replacement therapy within 3 months
Participant who is terminally ill, as defined as less than 3-months
expected survival
Decompensated chronic heart failure (to ensure that fluid overload is
not exacerbated by the additional sodium load from the intervention)
Bisphosphonate therapy (to avoid obscuring bone turnover effects;
patients with eGFR <30 mL/min/1.73 m2 should not usually be taking
bisphosphonates as this is a listed contraindication)
Uncontrolled hypertension at screening visit (BP >150/90 mmHg despite
use of four agents), unless evidence from home or 24-hour blood
pressure monitoring that blood pressure is usually controlled.
Subject participated in another clinical trial (other than observational
studies and registries) concurrently or within 30 days prior to screening
for entry into this study
Participant has a known allergy to sodium bicarbonate or lactose
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Healthcare Regulatory Agency (EudraCT number 2011-
005271-16) and the trial is registered at www.isrctn.com
(ISRCTN09486651). The trial is funded by the UK
NIHR Health Technology Assessment programme (ref:
10/71/01). The Sponsor is Tayside Academic Health
Sciences Centre, a joint initiative of the University of
Dundee and NHS Tayside, and trial management is via
Tayside Clinical Trials Unit (UKCTU number 49).Intervention
The study medication will be administered as oral tab-
lets. Placebo and active tablets will be identical in ap-
pearance. Bicarbonate tablets will contain 500 mg of
sodium bicarbonate (6 mmol sodium and 6 mmol bicar-
bonate); placebo tablets will be composed of lactose.
The Good Medical Practice (GMP)-compliant investiga-
tional medicinal product manufacturer (Legosan AB,
Kumla, Sweden) will prepare and bottle matching active
and placebo tablets for the trial. Participants willcommence therapy at a dose of 500 mg of oral sodium
bicarbonate or placebo three times per day; reflecting a
common starting dose in clinical practice. At 3 months,
if serum bicarbonate is found to be <22 mmol/L, the
dose will be increased to 1 g three times per day or pla-
cebo. This is equivalent to six tablets per day; larger
doses are likely to worsen adherence to therapy. This
dose is higher (3 g versus 1.8 g) than that used in a pre-
vious small RCT [13]; it is therefore likely to produce a
larger increment in bicarbonate at an earlier time point,
thus enhancing the ability of our trial to demonstrate
beneficial effects on outcome parameters.
Randomisation will be via a centrally controlled web-
based Good Clinical Practice (GCP)-compliant randomisa-
tion system, run by Tayside Clinical Trials Unit (TCTU).
Investigators at each site will access the web-based system
to allocate each participant at the end of the baseline visit.
Randomisation will be stratified by site. To ensure bal-
anced assignment across critical variables, a minimisation
algorithm will be employed, using baseline age, sex and
GFR category to balance allocation across trial arms.
To ensure that medication adherence is maximised,
we will employ a combination of written information
about the study medication and why taking it is import-
ant, together with aide memoirs including BiCARB-
branded mugs and fridge magnets. In the second year of
follow-up, regular telephone contact (at 15 and 21
months) will be made to remind participants about the
importance of medication adherence. Interventions in-
corporating these components have been shown in a
previous Cochrane review to enhance adherence [26]. If
the study drug needs to be stopped or the patient wishes
to stop they can remain in the study in order to perform
an intention-to treat-analysis.
Outcomes
The primary outcome for the trial is the between-group
difference in change for the Short Physical Performance
Battery (SPPB) between baseline and 12 months. The
SPPB is a validated measure of lower limb function that
reflects everyday activity. It is a powerful predictor of
subsequent disability, institutionalisation and death in
older people [27–29], and has more data validating its
use in older people than any other measure of physical
function. Secondary outcomes will include SPPB at other
time points, along with measures of physical function
(grip strength as measure of upper limb function, and
six minute walk as a measure of endurance capacity),
quality of life (generic, measured using the EQ-5D tool,
and disease-specific, measured using the KDQoL tool
[30]), anthropometry, renal function and bicarbonate
concentrations, markers of bone turnover, calcium and
phosphate metabolism, blood pressure and B-type natri-
uretic peptide. Key outcomes are listed in Table 2.
Table 2 Outcome measures and measurement points
OUTCOME TIMELINE
Screening Baseline 3 months 6 months 12 months 18 months 24 months
Informed Consent X
Inclusion/Exclusion Criteria X
Medical History/Demographics X
Adverse Events Recorded X X X X X X
Physical function measures
Short Physical Performance Battery X X X X X
Hand Grip Strength X X X X X
Six Minute Walk Test X X X X X
Blood measures
Sodium X X X X X X
Potassium X X X X X X
Creatinine X X X X X X
Urea X X X X X X
Bicarbonate X X X X X X
Estimated GFR X X X X X X
Calcium X X X X X
Phosphate X X X X X
Alkaline phosphatase X X X X X
Magnesium X X X X X
Albumin X X X X X
Haemoglobin X X X X X
Thyroid function X X X X X
HbA1c X X X X X
Total Cholesterol X X X X X
Cystatin C X X X X X
Study Biobank Samples X X X X X
Urine Sample
Protein/creatinine ratio X X X X X
Albumin/creatinine ratio X X X X X
Questionnaires
EQ-5D X X X X X
KDQoL X X X X X
Health Diary X X X X X
Falls Diary Xa X X X X X
Anthropometric Measurements
Mid-arm Circumference X X X X X
Triceps Skin Fold Thickness X X X X X
Mid-thigh Circumference X X X X X
Height X
Weight X X X X X
Vascular measures
Blood pressure and pulse X X X X X X
B-type natriuretic peptide X X X
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Table 2 Outcome measures and measurement points (Continued)
Bone and calcium metabolism
Calcium X X X X X
Phosphate X X X X X
Parathyroid hormone X X X
25-hydroxyvitamin D X X X
1,25 hydroxyvitamin D X X X
Tartrate-resistant acid phosphatase-5b X X X
Bone-specific alkaline phosphatase X X X
aadministered at baseline but not recorded until 3 months
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each study visit, as will data on hospitalisation, death (all-
cause, cardiovascular and renal), commencement of renal
replacement therapy, fractures, primary care and secondary
care outpatient visits via participant health-utilisation diar-
ies. Adherence to medication will be assessed by tablet
count on bottles returned to the trial pharmacy. Detailed
information on medical history, concomitant medications
(including renal and cardiovascular medications such as
renin-angiotensin system blockers), social and functional
history will be collected at baseline. Participant flow
through the trial is outlined in Fig. 1.Statistical analysis
Statistical analysis will be performed by intention-to-treat
and reported in accordance with the CONSORT statement
(www.equator-network.org). The primary analysis will be a
between-group comparison of 12 month outcomes, ad-
justed for baseline values of the outcome under test via re-
gression analysis. Further adjustment for age, sex and GFR
category will also be performed. Secondary analyses will
comprise multivariate repeated measures analysis using all
available time points, adjusted for baseline differences. A
per-protocol secondary analysis will be performed to com-
pare adverse events, and time-to-event analyses for death
or onset of renal replacement therapy will be performed
using Cox proportional hazards regression models. A two-
sided P value of 0.05 will be taken as significant for each
outcome. The primary outcome will be analysed at 12
months rather than 24 months in order to strike a balance
between excessive dropout (expected in this group of older,
multi-morbid participants) and sufficient time for the inter-
vention to show an effect.
Pre-specified subgroup analyses will include the follow-
ing: participants with a SPPB score of <10 (denoting a frai-
ler subgroup) versus those with SPPB ≥10; participants
with a baseline serum bicarbonate concentration of >18
mmol/L versus those with serum bicarbonate ≤18 mmol/L;
GFR category (4 versus 5); sex, and age >75 years versus
age ≤75 years. Missing data for the primary analysis will behandled using multiple imputation, provided that the as-
sumption of missing at random is met. Missing data in the
repeated measures analyses will be handled using general-
ised estimating equation approaches to maximise the use of
participants with incomplete data.Data analysis of health economic data
The economic analysis will estimate the healthcare costs
and quality of life associated with provision of bicarbonate
therapy relative to usual care (that is, usual healthcare man-
agement without the addition of bicarbonate therapy) over
the time period of the trial (12 months for the main ana-
lysis). It will determine the magnitude of the difference in
healthcare costs and quality of life between the two treat-
ments. Healthcare costs will include the type and duration
of hospital admissions, frequency of visits to hospital for
outpatient attendances, and other visits to/from relevant
healthcare professionals (for example, general practitioners,
nurse practitioners, and physiotherapists) at baseline and
over 12 months. Quality of life will be measured with the
EQ-5D instrument over an equivalent time period, and re-
sponses converted to a single summary score using pub-
lished UK quality of life weights, to produce a Quality
Adjusted Life Year, (‘QALY’) value. In addition to QALYs,
secondary analyses will include the measurement of well-
being and life satisfaction. Cost effectiveness acceptability
curves will be employed to show the probability that bicar-
bonate therapy is cost effective for different values of will-
ingness to pay per additional QALY [31]. These will be
developed using the quality of life gain and life expectancy
change estimates from the ANCOVA and repeated mea-
sures analysis. Cost differences will be modelled using gen-
eralized linear modelling, with appropriate adjustment for
skew and other baseline differences between groups. In
addition, non-parametric bootstrap methods will be used
for calculating confidence intervals around cost and QALY
differences. Sensitivity analysis will be undertaken for un-
certain parameters, such as alternative centre specific
costs per bed day and alternative age-adjusted quality of
life weights.
Fig. 1 Participant flow through trial
Witham et al. Trials  (2015) 16:326 Page 7 of 9A detailed statistical analysis plan will be agreed on
before the end of data entry and before the treatment
code is broken.
Sample size calculation
We plan to randomize a total of 380 participants: 190 to
bicarbonate and 190 to placebo. The clinically important
difference (CID) for the SPPB is a 1-point difference. As-
suming a SD of 2.6 as found in previous work [32], we
would require 143 patients per group to give 90 % power
to detect this difference at a two-sided alpha of 0.05. For
the EQ-5D, the minimum CID is 0.074 [33]. To detect
this with two-sided alpha = 0.05 and power of 90 %,assuming a SD of change of 0.2, as found in our previous
studies, our study requires 154 patients per group. We
anticipate a dropout rate of 10 % per 6 months, due to
the high rates of expected death and illness in this
multi-morbid, older group of participants; the calculated
sample size accounts for this dropout.
Progression to dialysis in a previous trial of bicarbonate
therapy [13] was lower in patients allocated to bicarbonate
(7 %) than in the control arm (33 %). The proposed sam-
ple size will have 90 % power to successfully detect a more
conservative difference of 7 % in the bicarbonate arm and
18 % in the control arm at 2 years. Assuming a 10 % loss
to follow-up every 6 months (a pessimistic estimate, based
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centre), we would require 380 patients to ensure adequate
power for the primary outcome and the EQ-5D at 12
months. This rate of attrition would leave 250 evaluable
patients at 2 years, which will give additional power to de-
tect smaller changes using repeated measures analyses.
Discussion
In many areas of medicine, older people are underrepre-
sented in clinical trials [34], and even when included,
older people in trials often lack the frailty and multi-
morbidity that characterise typical patients treated in
clinical practice. Hence the evidence base for many in-
terventions is not generalizable to typical older people.
Although oral bicarbonate is widely used to correct
acidosis in advanced CKD, this is not underpinned by
trial evidence, and real uncertainty exists regarding the
balance of benefit and risk for this intervention. As most
patients with CKD are old, and many are frail, it is crit-
ical that trials testing such interventions enrol typical pa-
tients and use outcome measures that are relevant to
older people. Few older people with even advanced CKD
will progress to end-stage renal disease; the risk of death
from cardiovascular disease or infection often super-
venes long before the need for renal replacement ther-
apy. The range of outcomes selected for this trial will
allow an estimation of overall net benefit or harm across
a range of disease outcomes including renal, bone and
vascular disease, as well as focusing on outcomes that
are important to patients (function and quality of life)
and policymakers (cost-utility analysis).
Three other randomised controlled trials with a projected
sample size >100 are either planned or in progress in this
area. One, a multicentre trial based in Italy [35], aims to
randomise 600 patients aged <80 years with GFR categories
3b or 4 and serum bicarbonate ≥18 mmol/L, and will com-
pare usual care with a strategy of maintenance of serum bi-
carbonate >24 mmol/L but <28 mmol/L for 3 years, using
doses of up to 4 g (48 mmol) of sodium bicarbonate per
day. The trial is randomised but is not blinded. The pri-
mary outcome is doubling of serum creatinine, with all-
cause mortality and requirement for renal replacement
therapy as secondary outcomes. This trial will be well
equipped to examine renal outcomes but will not focus on
physical function or quality of life, which are key outcomes
for older patients.
The second trial underway (NCT01452412; https://clini-
caltrials.gov), based in the United States, aims to recruit
150 patients with GFR categories 3b or 4 and serum bi-
carbonate 20 to 25 mmol/L, who will receive 0.4 mmol/
Kg/day of oral bicarbonate or placebo for 1 year. A
range of outcomes including insulin resistance, grip
strength, lower limb function, wrist bone mineral density,
renal function and proteinuria will be measured. This trialshould give useful information across a range of disease
states; the different population (milder acidosis and less
severe CKD) should complement the results from our
trial, but will not focus on health economic outcomes.
The third trial [36] is a single centre study being con-
ducted in Austria. It aims to recruit 200 patients with GFR
categories 3 or 4 and serum bicarbonate <21 mmol/L.
Participants will be randomised to one of two treatment
strategies - either high-dose oral bicarbonate supplementa-
tion (1.7 g to 5 g (60 mmol) per day) titrated to keep serum
bicarbonate >24 mmol/L, or a strategy of withholding bi-
carbonate unless serum bicarbonate falls below 19 mmol/L,
when low-dose oral bicarbonate will be administered with a
target serum bicarbonate of 20 mmol/L. The primary out-
come will be the effect of therapy on estimated GFR; sec-
ondary outcomes will include markers of bone metabolism,
the need for renal replacement therapy, and death. Treat-
ment and follow up will be for 2 years. The population
under study in this trial will have less severe CKD than the
BiCARB trial population, outcomes are predominantly fo-
cused on renal function, and the trial compares two strat-
egies of bicarbonate replacement, rather than bicarbonate
versus placebo as in the BiCARB trial.
In conclusion, the trial we describe should provide
much-needed evidence on the net risk-benefit balance
for this commonly used therapy in typical older patients
with advanced CKD. As such, the results should be dir-
ectly relevant to the care of this patient group and hence
be of value to clinicians and their patients, guideline de-
velopers and policymakers.
Trial status
At the time of writing, approximately 220 of the projected
380 participants have been randomised, and results are
expected in late 2018.
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